CAR T-cell Therapy in Multiple Myeloma: Finding Its Right Place - Episode 2

Sequencing CAR T in More Heavily Pretreated R/R MM as well in patients who deferred initial autologous HSCT

,

Experts discuss their clinical approach to using chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (R/R MM), focusing on how they sequence CAR T with other treatment options like autologous hematopoietic stem cell transplantation (HSCT) and bispecific antibodies.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Optimizing CAR T in R/R MM: Treatment Paradigms and Patient Selection
    Now Viewing
    EP. 2: Sequencing CAR T in More Heavily Pretreated R/R MM as well in patients who deferred initial autologous HSCT

    Video content above is prompted by the following:

    What is your clinical approach to CAR T-cell therapy in R/R MM? How are you typically sequencing CAR T with the other available treatment options like autologous HSCT and bispecifics?

    x